Empadiance-M 12.5/1000 is an oral combination tablet containing **Empagliflozin (an SGLT2 inhibitor)** and **Metformin (a biguanide)**, produced by Alhavi Pharmaceutical.
It is used to control blood glucose levels in adults with type 2 diabetes mellitus.
The complementary mechanisms of these two active ingredients enhance glycemic control — Empagliflozin promotes urinary glucose excretion, while Metformin decreases hepatic glucose production and improves insulin sensitivity.
Empadiance-M is available in two strengths: **5/1000 mg** and **12.5/1000 mg** tablets.
Empadiance-M 12.5/1000 (Empagliflozin + Metformin)
Dosage form: Tablet
Empadiance-M 12.5/1000 is indicated for:
• Control of blood glucose levels in adults with type 2 diabetes mellitus requiring combination therapy with Empagliflozin and Metformin
• Can be used as an adjunct to diet and exercise, alone or in combination with other antidiabetic agents
The dual mechanism provides effective and complementary glycemic control through enhanced glucose excretion and improved insulin response.
• Recommended dose: **12.5/1000 mg once or twice daily**, as prescribed by a physician
• Take **with or after meals** to minimize gastrointestinal side effects caused by Metformin
• Swallow tablets whole with water — do not crush or chew
• Continue diet and exercise as advised by your healthcare provider
• Use under medical supervision with regular monitoring of blood glucose and kidney function